权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Circulating tumor cells in hepatocellular carcinoma

肝细胞癌中的循环肿瘤细胞

基本信息

批准号：
8721366
负责人：
Mehmet Toner
金额：
$ 8.44万
依托单位：
MASSACHUSETTS GENERAL HOSPITAL
依托单位国家：
美国
项目类别：
财政年份：
2013
资助国家：
美国
起止时间：
2013-09-01 至 2016-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8721366
关键词：
Achievement Aftercare Antibodies Biological Assay Biological Markers Biopsy Biopsy Specimen Blood Blood donor Cell Separation Cells Clinical Clinical Medicine Data Detection Devices Diagnosis Disease Early Diagnosis Early treatment Enrollment Europe Evaluation Excision Future Goals Gold Hepatic Mass Laboratories Liver Magnetic Resonance Imaging Malignant Epithelial Cell Malignant Neoplasms Malignant neoplasm of liver Medical Medicine Microfluidics Monitor Neoplasm Circulating Cells Operative Surgical Procedures Organ Pathologist Patients Pilot Projects Primary Neoplasm Primary carcinoma of the liver cells Radiation Randomized Clinical Trials Recurrence Reproducibility Research Resected Risk Sensitivity and Specificity Staging Surface Survival Rate Technology Testing Tissues Transplantation Tumor Burden Ultrasonography Venous Whole Blood X-Ray Computed Tomography alpha-Fetoproteins base cohort cost effective diagnostic accuracy improved liver transplantation neoplastic cell public health relevance screening tool

项目摘要

DESCRIPTION (provided by applicant): We propose to use an antibody-coated microfluidic surface-capture device, the Herringbone CTC-chip, to isolate hepatocellular carcinoma (HCC) circulating tumor cells (CTCs) from venous blood. Successful isolation of these cells from the venous blood of HCC patients has the potential to substantially improve current medical practice by enabling early detection and monitoring of therapy in HCC patients. Survival from HCC is entirely dependent on early detection whether its detection of the primary tumor or recurrence after treatment. Screening, early diagnosis and detection of recurrence have been formidable challenges and despite massive worldwide research efforts, the five-year survival rate of HCC patients remains to be poor. We propose to develop and optimize the CTC-chip for HCC CTC isolation (Aim 1). We will then determine the diagnostic accuracy of the CTC analysis compared to biopsy evaluation of unknown liver masses (Aim 2). The critical value of Aim 2 is to determine the sensitivity and the specificity of the technology to detect HCC CTCs in patients with cancer (n=40) and without cancer (n=40).

描述（由申请人提供）：我们建议使用抗体包被的微流体表面捕获装置，人字形CTC芯片，从静脉血中分离肝细胞癌（HCC）循环肿瘤细胞（CTC）。从HCC患者的静脉血中成功分离这些细胞有可能通过早期检测和监测HCC患者的治疗来显著改善当前的医疗实践。HCC的生存完全依赖于早期检测，无论是原发肿瘤的检测还是治疗后的复发。筛查、早期诊断和复发检测一直是艰巨的挑战，尽管世界范围内进行了大量的研究工作，但HCC患者的五年生存率仍然很低。我们建议开发和优化用于HCC CTC分离的CTC芯片（目标1）。然后，我们将确定CTC分析与未知肝脏肿块的活检评估相比的诊断准确性（目的2）。目标2的临界值是确定该技术在癌症患者（n=40）和非癌症患者（n=40）中检测HCC CTC的灵敏度和特异性。